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Abstract
Background: In October 2009, 7-valent pneumococcal conjugate vaccine (PCV7: PrevenarTM Pfizer) was replaced in
the Northern Territory childhood vaccination schedule by 10-valent pneumococcal Haemophilus influenzae protein
D conjugate vaccine (PHiD-CV10; Synflorix™ GlaxoSmithKline Vaccines). This analysis aims to determine whether the
reduced prevalence of suppurative otitis media measured in the PHiD-CV10 era was associated with changes in
nasopharyngeal (NP) carriage and middle ear discharge (ED) microbiology in vaccinated Indigenous children.
Methods: Swabs of the NP and ED were collected in remote Indigenous communities between September 2008
and December 2012. Swabs were cultured using standardised methods for otitis media pathogens. Children less
than 3 years of age and having received a primary course of 2 or more doses of one PCV formulation and not
more than one dose of another PCV formulation were included in the primary analysis; children with non-mixed
single formulation PCV schedules were also compared.
Results: NP swabs were obtained from 421 of 444 (95 %) children in the PCV7 group and 443 of 451 (98 %)
children in the PHiD-CV10 group. Non-mixed PCV schedules were received by 333 (79 %) and 315 (71 %) children,
respectively. Pneumococcal (Spn) NP carriage was 76 % and 82 %, and non-typeable Haemophilus influenzae (NTHi)
carriage was 68 % and 73 %, respectively. ED was obtained from 60 children (85 perforations) in the PCV7 group
and from 47 children (59 perforations) in the PHiD-CV10 group. Data from bilateral perforations were combined.
Spn was cultured from 25 % and 18 %, respectively, and NTHi was cultured from 61 % and 34 % respectively
(p = 0.008).
Conclusions: The observed reduction in the prevalence of suppurative OM in this population was not associated
with reduced NP carriage of OM pathogens. The prevalence of NTHi-infected ED was lower in PHiD-CV10
vaccinated children compared to PCV7 vaccinated children. Changes in clinical severity may be explained by the
action of PHiD-CV10 on NTHi infection in the middle ear. Randomised controlled trials are needed to answer this
question.
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Background
In October 2009 the PCV schedule for our region was
changed from PCV7/PPV23 to PHiD-CV10 (Table 1).
We recently reported a reduction in the prevalence of
suppurative OM (either acute otitis media without per-
foration (AOMwoP), AOM with perforation (AOMwiP),
or chronic suppurative OM (CSOM)) in PHiD-CV10-
vaccinated children (39 %) compared to PCV7-
vaccinated children (51 %) [1]. There was a concomitant
increase in the prevalence of otitis media with effusion
(OME) from 41 % in PCV7- to 51 % in PHiD-CV10-
vaccinated children. Three key factors were found to be
associated with the reduction in suppurative OM and in-
crease in OME; i) PHiD-CV10 was protective compared
to PCV7, ii) living in a household with more children
less than 5 years of age per household was a risk factor,
and iii) older age was protective of suppurative OM. Re-
cent prescribing of antibiotics, child care attendance and
other measured factors were not obviously associated
with suppurative OM. Parents of the children in the sur-
vey were asked to consent to their child having a naso-
pharyngeal (NP) swab and a swab(s) of middle ear
discharge (ED) if tympanic membrane perforation
(TMP) was present (either AOMwiP or CSOM).
Streptococcus pneumoniae (pneumococcus, Spn) and
non-typeable Haemophilus influenzae (NTHi) are major
pathogens detected by culture [2, 3] and PCR [4] in ED
of Australian Indigenous children with AOMwiP or
CSOM. By culture, H. influenzae, S. pneumoniae, and
M. catarrhalis were detected in 49 %, 33 % and 4 %, re-
spectively of 55 ears diagnosed as AOMwiP whereas
qPCR identified these pathogens in 89 %, 41 % and
18 %, respectively of ED swabs [4]. The reduction in
prevalence of suppurative OM and concomitant increase
in OME (i.e. relative improvement in OM severity) asso-
ciated with the PHiD-CV10 schedule used in the NT
could be mediated by differences in vaccines, either their
component antigens or the level of immune protection
in the middle ear [5]. PHiD-CV10 has an additional
three pneumococcal serotypes (1, 5 and 7F) and poten-
tial NTHi protection due to conjugation of several sero-
types with H. influenzae protein D [6]. It is also possible
that the selective pressure of 10-valent vaccine may have
further altered pneumococcal replacement and pneumo-
coccal serotype distribution (although to date there is
little evidence of this) [7]. Although the first
pneumococcal protein D conjugate vaccine trial
found efficacy of 11-valent pneumococcal protein D
conjugate vaccine (11Pn-PD) against all-cause AOM,
NTHi-AOM [6], and NTHi NP carriage [8], recently
published PHiD-CV10 trials have shown no impact
against NTHi NP carriage [7], or NTHi-AOM [9]. In
the latter study, vaccine efficacy for all-cause AOM
was 19 % [95 % CI 4.4 to 31.4] in intention-to-treat
(ITT) analysis compared to 16 % [95 % CI-1.1 to
30.4] in according-to-protocol (ATP) analysis [9].
Our study compared the prevalence of all forms of
OM and NP carriage of OM pathogens in young
children receiving predominantly PCV7 or PHiD-
CV10 according to NT childhood vaccination sched-
ules. In this paper, we assess whether a change in se-
verity of OM seen in the PHiD-CV10 era was
accompanied by a change in the prevalence of OM
pathogens in the NP or middle ear.
Methods
Study design, setting, community recruitment and ethical
approval
This report includes cross-sectional data from 25 com-
munities participating in at least one community-based,
cross-sectional survey of OM and NP carriage between
September 2008 and December 2012. The study was ap-
proved by the Human Research Ethics Committee of the
NT Department of Health and the Menzies School of
Health Research (EC00153), and the Western Australian
Aboriginal Health Information and Ethics Committee
(WAAHIEC). Each community council provided written
approval of the study to the Ethics committee. Written
informed consent was obtained from parents or carers
for their child (regardless of ear health status or history)
to have an ear examination, NP swab, swab of ED if
present, and general child health check. Parents or
carers were also asked to provide written permission to
access the mother’s and the child’s medical records and
to complete a lifestyle interview regarding information
on likely risk factors for OM and NP carriage of OM
pathogens. The Ethics committees approved this process
and approved all participant recruitment processes, con-
sent forms, participant information sheets and
questionnaires.
Participant recruitment and consent
In these remote communities where the birth cohort is
between 5 and 45 infants per year, we aimed primarily to
see all children under 36 months of age as well as older
children (up to 6 years of age) if available. Individual
families were approached with information about the
study. Aboriginal children between 0 and 6 years of age,
resident in participating communities, and whose
Table 1 Pneumococcal vaccines in the Childhood Vaccination
Schedule for Northern Territory Indigenous children
Date commenced Vaccine Age (mo)
1st July 2001 PCV7 & PPV23 2,4,6,18
1st October 2009a PHiD-CV10 2,4,6,18
1st October 2011 PCV13 2,4,6,18
aNo other Australian jurisdiction recommended that PHiD-CV10 replace PCV7
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parents or carers provided signed consent, were eligible
for surveillance.
Microbiology
NP swabs were collected, transported and stored as pre-
viously described [10] and in accordance with WHO rec-
ommendations for pneumococcal NP carriage studies
[11]. Swab quality was also recorded as good (swab
inserted to the NP and held for 5 s), fair (swab inserted
partially and briefly), poor (swab of skin just below the
nose) or very poor (of skin just below the nose and no
discharge visible). Any swab with visible secretions was
coded as good. Swabs of ED were collected after clean-
ing the external canal and collecting discharge from as
close as possible to the TMP [10]. NP and ED swabs
were cultured on selective and non-selective media and
semi-quantitative colony counts recorded as previously
described [10]. For ED swabs with swarming species that
precluded selection of single NTHi colonies, a millipore
filtration step was used [10]. At least 2 presumptive
pneumococcal colonies and 2 presumptive NTHi col-
onies were selected from each specimen for confirm-
ation. Colonies of minority colony morphology were
chosen if present. Pneumococci were identified by col-
ony morphology, optochin sensitivity and positive reac-
tion with typing sera (Statens Serum Institut, Denmark);
serotype was determined by Quellung reaction. NTHi
were identified by colony morphology, dependence on X
and V growth factors, and Phadebact agglutination. PCR
discrimination of H. haemolyticus was not uniformly
undertaken after confirmation that less than 0.2 % pre-
sumptive NTHi isolates from NP swabs in this popula-
tion are misidentified [12]. Antimicrobial susceptibility
was determined by the calibrated dichotomous suscepti-
bility (CDS) disc diffusion method [13, 14]. Minimum
inhibitory concentrations (MICs) were determined for
macrolide and beta-lactam antibiotic resistance in S.
pneumoniae isolates and azithromycin resistance in
NTHi isolates using Etest strips (AB bioMérieux,
Sweden). Beta-lactamase production by NTHi was deter-
mined using nitrocephin (Oxoid, Australia). Resistance
was defined using European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) breakpoints
(http://www.eucast.org). Penicillin non-susceptibility of
Spn was defined as MIC > 0.06 mg/L and azithromycin
resistance as MIC > 0.5 mg/L. Azithromycin resistance
in NTHi was defined as MIC > 4 mg/L; intermediate re-
sistance as MIC > 0.12 mg/L and ≤ 4 mg/L, and suscepti-
bility as MIC ≤ 0.12 mg/L.
Clinical assessments
Ear examinations and general health assessments
All clinical assessments and diagnoses were made ac-
cording to previously reported clinical outcomes of this
surveillance [1]. In this report we describe the microbiol-
ogy of ED from cases of AOMwiP or CSOM. We define
AOMwiP as ED observed and TMP either recently
healed or present for less than six weeks or covering less
than 2 % of the pars tensa of the TM, and CSOM as ED
observed and TMP present for longer than six weeks or
covering at least 2 % of the pars tensa of the TM. We
also refer to combination categories of any suppurative
OM (any AOMwoP, AOMwiP or CSOM) and any TMP
(any AOMwiP, dry perforation or CSOM). Where dur-
ation of discharge was not known, size of perforation
was used to distinguish AOMwiP and CSOM. We asked
the mother if she thought her child had ear pain that
day or during the previous evening. These a priori diag-
nostic criteria have been applied in all our surveillance
and clinical trials conducted in this population since
2001 [15].
Medical record review
The child’s medical records were reviewed to obtain
dates of vaccinations, recent clinic presentations, antibi-
otics prescribed within the previous 5 weeks, sex, gesta-
tional age, date of birth, birth weight, and latest
haemoglobin result.
Risk factor questionnaires
The parent or guardian (usually the mother) was asked a
standardised set of questions about common risk factors
for OM, including the number of siblings, numbers of
people and other children (less than 5 years of age) liv-
ing in the child’s house, whether the mother or child’s
siblings had ever had TMP (“runny ears”), her schooling
and highest level of education, if she smoked, and
whether the child was exposed to campfire smoke within
the previous week, the number of days per week that the
child attended child care, whether the child washed with
soap the previous day, had ever used a pacifier, or was
ever breastfed.
Statistical analysis
Univariate analyses compared children who had received
at least 2 doses of PCV7 with children who had received
at least 2 doses of PHiD-CV10 as their primary course
vaccines, with or without a subsequent single dose of an
alternative PCV, or PPV23. Chi squared tests (and t-tests
for several risk factors in Additional file 1: Table S1)
were used. For this analysis we included only the first
visit of children 0 to 36 months of age. Comparisons of
children receiving non-mixed PCV schedules were also
made. Confidence intervals (CI, 95 %) and risk differ-
ences (RD, 95 % CI) were calculated where appropriate.
Stata version 12 was used for all data analyses [16].
Multivariate logistic regression analyses for pathogen-
specific NP carriage and ED culture included all the risk
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factor and demographic variables for which significant
p values (<0.05) were obtained for odds ratios in univari-
ate analyses. Variables remained in the model if p<0.05.
Where odds ratios are reported, they have come from
logistic regression models, where adjustment for com-
munity was made using random effects. A global test
was performed for categorical risk factors.
Missing data
If participants declined a clinical assessment or a swab,
the data were coded as missing. If parents or carers re-
fused or were unsure of their response to an interview
question, we also coded this as missing. Missing data
were then excluded from the denominator for summary
statistics.
Results
Participant exclusions and PCV vaccination status of NP-
swabbed children
As previously described [1], we enrolled 1,027 children
and made 1,088 child visits in remote communities in
the tropical Top End region of Australia; 895 children
met inclusion criteria [1]. NP swabs were obtained from
421 of 444 (95 %) children in the PCV7 group and 443
of 451 (98 %) children in the PHiD-CV10 group. Non-
mixed PCV schedules were received by 333 (79 %) and
315 (71 %) children, respectively. All 864 children in-
cluded in this analysis had received two or more doses
of appropriate vaccine and not more than one dose of
any other PCV. Included and excluded schedules are de-
tailed in Table 2.
Participant characteristics, general health and antibiotics
prescribed
Due to the high proportion of swabs collected, charac-
teristics (e.g. age, gestational age, birth weight, gender,
general health) of swabbed children in PCV7 and PHiD-
CV10 groups (Table 3) were very similar to those previ-
ously described for these groups within the whole cohort
[1]. As reported previously, the five largest communities
contributed 59 % data to each group. Of note, the preva-
lence of any suppurative OM, antibiotics prescribed,
runny nose and cough were the same in the subset of
NP-swabbed children (Table 3) as was previously
reported.
NP carriage
NP swabs from four of 864 children were not processed.
No significant differences between the PCV7 and PHiD-
CV10 groups were found for carriage prevalence of
NTHi (68 % and 73 %, respectively), Spn (76 % and
82 %) or Moraxella catarrhalis (Mcat) (48 % and 43 %)
or NTHi and Spn combined carriage (64 % and 68 %).
Staphylococcus aureus (Sa) NP carriage was significantly
lower in the PHiD-CV10 group (32 % and 21 %), and
Mcat was lower when non-mixed schedules were com-
pared (Table 4). Most children (86 % and 91 %, respect-
ively) carried one or other of these pathogens. A
comparison of NP carriage among children who received
non-mixed PCV schedules gave similar results, although
the difference between groups in Mcat was more pro-
nounced (Table 4).
Pneumococcal serotypes in the NP
The most frequent colonisers in the PCV7:PHiD-
CV10 groups respectively, were 16F (12 % :14 %) 19A
(10 %:8 %), and 11A (9 %:8 %). Serotypes 23B, 19F
and 6C were the next most frequent colonisers in the
PCV7 group; 10A, 6C and 15A in the PHiD-CV10
group. PCV13 serotypes colonised fewer children in
the PHiD-CV10 group (21 %) than the PCV7 group
(29 %) (Table 4 and Figs. 1 and 2). In the PCV7
group 39 % (128/326) Spn isolates were susceptible to
both penicillin and azithromycin, 37 % were penicillin
non-susceptible, 14 % were azithromycin non-
susceptible and a further 8 % were non-susceptible to
both. In the PHiD-CV10 group, 44 % (163/373) Spn
isolates were susceptible to both penicillin and azi-
thromycin, 39 % were penicillin non-susceptible, 6 %
Table 2 Number of doses of pneumococcal vaccine received by
421 NP-swabbed PCV7 children and 443 NP-swabbed PHiD-CV10
children
Doses of PCV7 Doses of PHiD-CV10 TOTAL
0 1 2 3 4
0 30c 18 c 48 278 78 404
1 4 c 2 c 23 15 1 39
2 26 13 30 c 39
3 305 72 1 c 377b
4 4 1 5
+ PPV23a 132a
+ PCV13b 2b 0 19b 69b 1b 91b
TOTAL 335 86 71 293 79 864
PCV7 7-valent pneumococcal conjugate vaccine
PHiD-CV10 10-valent pneumococcal Haemophilus influenzae protein D
conjugate vaccine
PCV13 13-valent pneumococcal conjugate vaccine
Included mixed schedules:
a 132 swabbed children also received one dose PPV23 (ceased in
October 2010)
b 91 swabbed children also received one dose PCV13:
2 of 305 PCV7 3-dose children
19 of 48 PHiD-CV10 2-dose children
69 of 278 PHiD-CV10 3-dose children
1 of 78 PHiD-CV10 4-dose child
Excluded schedules
c 85 swabbed children were excluded, plus two additional children (not shown
in Table 1) who received two doses of PHiD-CV10 and two doses of PCV13
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were azithromycin non-susceptible, and a further 9 %
were non-susceptible to both.
NP swab quality
NP swab quality was recorded for 393 of 421 (93 %) and
361 of 443 (81 %) NP swabs collected from PCV7 and
PHiD-CV10 children, respectively. Most swabs (92 %)
were good or fair quality, 2 were very poor quality; 23
were swabs of secretions collected by nose blowing into
a tissue. Recovery of NTHi, Spn or Sa was not signifi-
cantly different for different quality swabs or swabs with
missing data on quality.
Recovery of OM pathogens from ED
We collected 144 ED swabs from 60 children (85 ears)
in the PCV7 group and 47 children (59 ears) in the
PHiD-CV10 group (Table 5). Despite use of selective
media and filtration methods [10], overgrowth by
swarming species on agar plates (hereafter referred to as
masking) affected recovery of NTHi from 12 EDs in the
PCV7 group and 4 in the PHiD-CV10 group, Spn from
2 and 3, and Mcat from 24 and 4, respectively. Of the
ED swabs where recovery of NTHi was not affected by
masking, NTHi was cultured from a greater proportion
of EDs in the PCV7 group (53 %) compared to the
Table 3 Participant characteristics, general health and antibiotics prescribed, by vaccination group
PCV7 PHiD-CV10 Absolute Difference in mean or % [95 %
CI]
P
n/N Mean (SD) or
%
n/N Mean (SD) or
%
Age (mo) 421 20 (8) 443 18 (7) 2 0.0001
[1 to 3]
< 1 year 88 21 % 113 26 %
1 to < 2 years 182 43 % 218 49 %
2 to < 3 years 151 36 % 112 25 %
Gestational age (weeks) 346 37.8 (2.8) 418 38.1 (2.2) 0.3 0.03
[0 to 0.7]
< 32 weeks 15 4 % 8/418 2 %
Birth weight (kg) 358 2.97 (0.64) 423 3.06 (0.61) 0.08 0.03
[0.00 to 0.17]
< 3 kg 174 49 % 192 45 %
Sex (female) 196/
421
47 % 228/
443
51 % 5 % 0.15
[−2 to 12]
GENERAL HEALTH & ANTIBIOTICS
RECENTLY PRESCRIBED
Runny Nose 160/
413
39 % 195/
437
45 % 6 % 0.08
[−1 to 12]
Any cough 80/416 19 % 169/
439
38 % 19 % <0.0001
[13 to 25]
Any suppurative OM 209/
404
52 % 165/
424
39 % −13 % 0.0002
[-20 to −6]
Any antibiotics prescribed in previous
5 weeks
119/
421
28 % 184/
443
42 % 13 % <0.0001
[7 to 20]
Beta-lactam 95/421 23 % 155/
443
35 % 12 % 0.0001
[6 to 18]
Macrolide 13/421 3 % 18/443 4 % 1 % 0.44
[−1 to 3]
Topical 17/421 4 % 18/443 4 % 0 % 0.99
[−3 to 3]
Haemoglobin (<11 mg/dL) 115/
385
30 % 137/
398
34 % 5 % 0.17
[−2 to 11]
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PHiD-CV10 group (35 %). Similarly, Spn was cultured
from 24 % and 14 %, Mcat from 2 % and 7 %, and Sa
from 54 % and 43 %, respectively. When data from chil-
dren with bilateral discharge were combined, results
were similar, although the difference in NTHi was more
pronounced (RD −27 % [95 % CI −46 to −8] p = 0.008)
(Table 5). We found no significant differences in recov-
ery of any OM pathogen from EDs from AOMwiP com-
pared to CSOM (data not shown).
Pneumococcal serotypes in ED
Isolates from three of four bilateral Spn-positive EDs
were the same serotype, and were included once in ana-
lysis. We serotyped 27 first isolates, 20 second, 3 third
and 3 fourth isolates from the 30 Spn-positive ED speci-
mens. Only one of 26 second, third or fourth isolates, a
serotype 19A, was different to the first isolate, an 11A.
Of the 27 first isolates serotyped, 17 were from the
PCV7 group and 10 from the PHiD-CV10 group.
Table 4 Prevalence of NP carriage of OM pathogens in NP-swabbed children, by vaccination group
PCV7 PHiD-CV10 Absolute Risk Difference P
value[95 % CI]
n/N % n/N %
NP carriage
NTHi 284/420 68 % 322/440 73 % 6 % 0.07
[−0.5 to 12]
Spn 321/420 76 % 359/440 82 % 5 % 0.06
[−0.2 to 11]
Mcat 202/420 48 % 189/438 43 % −5 % 0.15
[−12 to 2]
Sa 136/420 32 % 94/440 21 % −11 % 0.0003
[−17 to −5]
Combination NP carriage categories
Spn and NTHi 267/420 64 % 297/440 68 % 4 % 0.23
[−2 to 10]
Spn or NTHi 361/420 86 % 400/440 91 % 5 % 0.02
[0.6 to 9]
PCV7 types 38/319 12 % 31/372 8 % −4 % 0.12
[−8 to1]
PCV13 types 92/319 29 % 77/372 21 % −8 % 0.01
[−15 to −2]
Serotypesb 16Fcd(12 %) 19Acd(10 %) 11Acde 23Bcde 6Cc = 19Fde
23Fcde = 6Aa = 10Ad 33F
16Fd(14 %) 19Ade(8 %) 11Ade 10Ad 6Cc 15Ade
23Fcde 21c 23Bd 35F
Non-mixed PCV schedules
NP carriage 333a 314
NTHi 225/332 68 % 230/314 73 % 5 % 0.13
[−2 to 12]
Spn 253/332 76 % 259/314 82 % 6 % 0.05
[0 to 12]
Mcat 172/332 52 % 127/313 41 % −11 % 0.004
[−19 to −4]
Sa 105/332 32 % 70/314 22 % −9 % 0.008
[−16 to −2]
a125 children in the PCV7-only group had also received PPV23
bStrains within serotypes that are:
c Azithromycin non-susceptible (MIC > 0.5 mg/L)
d Penicillin non-susceptible (MIC > 0.06 mg/L)
e Non-susceptible to both
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Overall, 17 serotypes were detected. The hierarchy of 12
serotypes in the PCV7 group was 10A (n = 4), 7F (n = 2),
11C (n = 2) and one each of 10F, 12F, 16F, 17F, 19A,
19F, 23F, 6A and 6C. The hierarchy of seven serotypes in
the PHiD-CV10 groups was 11A(n = 2) and one each of
15A, 16F, 19F, 21, 22A and 35F. Five of the seven sero-
types in the PHiD-CV10 group had not been detected in
the PCV7 children and 10 of the 12 serotypes in the
PCV7 group were not detected in the PHiD-CV10
group; only 16F and 19F were common.
23-valent pneumococcal polysaccharide vaccine (PPV23)
PPV23 was received by 132 NP-swabbed children in the
PCV7 group. In a post-hoc analysis, we previously
reported that the PCV7-PPV23 group had a higher pro-
portion of TMP than PCV7-only children. Compared to
38 age-eligible children who received PCV7-only, NP
carriage of Spn in the PCV7-PPV23 group was not sig-
nificantly different (77 % in the PCV7-PPV23 group and
76 % in the PCV7-only group). Similarly for ED swabs,
11 of 40 (28 %) ED swabs from children with PPV23
vaccination cultured Spn compared to 1 of 5 (20 %) not
PPV23 vaccinated.
Risk factors
Questionnaire response
Of the 421 NP-swabbed children in the PCV7 group,
392 (93 %) parents or carers consented to a structured
Fig. 1 Pneumococcal serotypes and antimicrobial susceptibility of isolates colonising the nasopharynx of the PCV7 group. The first isolate selected per
NP swab is included. Serotype is ordered by pneumococcal vaccine group: PCV7, PHiD-CV10, PCV13, 23PPV and non-vaccine types (notPV and
Omniserum-negative). Penicillin non-susceptibility was defined as MIC > 0.06 mg/L. Azithromycin resistance was defined as MIC > 0.5 mg/L
Fig. 2 Pneumococcal serotypes and antimicrobial susceptibility of isolates colonising the nasopharynx of the PHiD-CV10 group. The first isolate
selected per NP swab is included. Serotype is ordered by pneumococcal vaccine group: PCV7, PHiD-CV10, PCV13, 23PPV and non-vaccine types
(notPV and Omniserum-negative). Penicillin non-susceptibility was defined as MIC > 0.06 mg/L. Azithromycin resistance was defined
as MIC > 0.5 mg/L
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Table 5 Prevalence of OM pathogens in 144 ear discharge (ED) swabs from 107 children with AOMwiP or CSOM, by vaccination
groups
PCV7 PHiD-CV10 Absolute Risk Difference [95 % CI] P value
N, Mean (SD) % N, Mean (SD) %
ED swabs 85 59
Children with ED 60a 47
Mean age (mo) 20 (7.6) 18 (6.9)
Bilateral ED swabs 19 13
CSOM 11 8
AOMwiP 6 3
AOMwiP and CSOM 2 2
All ED swabs 85 59
> =3-dose schedule 77/85 91 % 53/59 90 %
One dose PCV13 0 9/59 15 %
NTHi 39/73m- 53 % 19/55 35 % −19 % 0.03
[−36 to −2]
Spn 20/83 24 % 8/56 14 % −10 % 0.16
[−23 to 3]
NTHi and Spn 12/69 17 % 5/55 9 % −8 % 0.18
[−20 to 3]
Mcat 1/61 2 % 4/55 7 % 6 % 0.14
[−2 to 13]
Sa 44/82 54 % 24/56 43 % −11 % 0.21
[−28 to 6]
Spn serotypesb 10A(n = 4) 7Fc(n = 2) 11Cd(n = 2)
10F 12F 16Fd 17Fc 19Ad 19Fd 23Fc
6A 6C
11Ad(n = 2) 15Ac 16Fd
19Fd 21 22A 35F
Children with ED (Bilateral data combined) 60 47
> =3 dose schedule 54/60 90 % 42/47 89 %
One dose PCV13 0 9/47 19 %
NTHi 33/54m- 61 % 15/44 34 % −27 % 0.008
[−46 to −8]
Spn 15/60 25 % 8/45 18 % −7 % 0.38
[−23 to 8]
NTHi and Spn 11/60 18 % 5/45 11 % −7 % 0.31
[−21 to 6]
Mcat 1/46 2 % 3/44 7 % 5 % 0.27
[−4 to 13]
Sa 35/59 59 % 22/45 49 % −10 % 0.29
[−30 to 9]
a 53 children in the PCV7 group had also received PPV23
b Strains within this serotype are:
c Azithromycin non-susceptible (MIC > 0.5 mg/L)
d Penicillin non-susceptible (MIC > 0.06 mg/L)
e Non-susceptible to both
f- ED culture not affected by masking
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risk factor questionnaire conducted by interview,
whereas only 289 (65 %) parents or carers of the 443
NP-swabbed children in the PHiD-CV10 group con-
sented to the interview. Despite these differences in re-
sponse rates, NP carriage among responders was similar
to NP carriage in the whole NP-swabbed cohort. Fur-
thermore, within the PHiD-CV10 group, NP carriage
was similar for the consented and non-consented chil-
dren (NTHi: 71 % versus 76 %, respectively; Spn: 82 %
versus 80 %, respectively).
Prevalence of risk factors
Similar risk factor prevalence rates were found for the
NP-swabbed children (Additional file 1: Table S1) as pre-
viously reported [1]. Briefly, the mean number of chil-
dren less than 5 years of age per household was lower in
the PHiD-CV10 group. Other risk factors were compar-
able between PCV7 and PHiD-CV10 groups.
Risk factors associated with NP carriage of (i) NTHi and (ii)
Spn
In univariate analyses, vaccine group was not associated
with lower NP carriage of NTHi or Spn (Table 6). The
number of children less than 5 years of age in the house-
hold was associated with increased risk of NTHi car-
riage, maternal schooling was protective, and low
haemoglobin level (<11 mg/l) was a risk factor. In the
multivariate analyses (data not shown) with these vari-
ables, maternal schooling and low haemoglobin were
significantly associated with NP carriage of NTHi. Ad-
justment for age made no substantial difference to these
findings. Pacifier use and recent antibiotic prescribing
were protective of Spn carriage, and breast feeding was a
risk factor in the univariate analyses. In the multivariate
analyses, breast feeding and pacifier use remained sig-
nificant. After adjustment for age, both dropped out of
the model (the effect of PHiD-CV10 remained similar to
that reported in Table 6).
Risk factors and ED microbiology
No risk factors (other than PHiD-CV10 for NTHi) were
associated with the reduced culture of NTHi or Spn
from ED.
Discussion
We recently reported a reduction in the prevalence of
suppurative OM and a concomitant increase in OME
prevalence in PHiD-CV10-vaccinated children compared
to PCV7-vaccinated children [1]. Our parallel NP car-
riage surveillance and opportunistic collection of ED
from children with either AOMwiP or CSOM provide
data to help interpret clinical findings.
We report here that the NP carriage prevalence of
NTHi and Spn was fairly similar in the PHiD-CV10
group compared to the PCV7 group. Most children had
received three or more doses of one PCV, and a com-
parison of non-mixed schedules was consistent with the
lack of difference between PCV groups. This is in con-
trast to NP carriage of Mcat and Sa, two minor OM
pathogens, which were lower in the PHiD-CV10 group
compared to the PCV7 group. In the multivariate logis-
tic regression analyses, maternal schooling (year 11 or
12 completion compared to year 10 or less) was associ-
ated with less NTHi NP carriage, and low haemoglobin
was a risk factor. Anaemia is very common among Abo-
riginal children in remote communities [17] and is an
important risk factor for acute lower respiratory tract in-
fection in developing countries [18].
Our data on the microbiology of ED collected from
children with either AOMwiP or CSOM are particularly
interesting as they describe a reduction in NTHi culture
from the ED of PHiD-CV10-vaccinated children com-
pared to PCV7-vaccinated children. Furthermore, there
was no vaccine group difference in Spn culture from
EDs, or other OM pathogens. This suggests that there
may be a compartmental effect of PHiD-CV10-induced
immune response in the ear compared to the NP.
Whilst we understand the NP to be the source of
pathogens that cause middle ear infections, we suspect
that vaccine-induced immune responses could deliver
protection in the middle ear, where numbers of organ-
isms are likely to be lower, without eliminating NP car-
riage. This hypothesis is plausible (not all NP colonised
children have OM), and should be confirmed in rando-
mised controlled vaccine trials with OM outcomes and
concomitant studies of NP and, if possible, MEF micro-
biology. Indeed the 11Pn-PD trial (POET study) showed
a significant 35 % reduction in NTHi-positive MEF from
children vaccinated with 11Pn-PD compared to controls
[6]. A significant reduction in NP carriage was also re-
corded, but only three months following the booster
(4th) dose [8]. The data from PHiD-CV10 have been less
convincing with no significant impact on NP carriage of
NTHi being reported from an observational study [7] or
a randomised controlled trial (RCT) [19]. The latter
RCT included analyses of colonisation density which
was also not different between PHiD-CV10 and PCV7
groups. In Kilifi, analysis of NP carriage prior to and fol-
lowing PHiD-CV10 introduction to the national vaccin-
ation schedule found NP carriage of NTHi in children
under 5 years of age was 54 % before PHiD-CV10 intro-
duction and 40 % after introduction (adjusted prevalence
ratio 0.62) [20]. Almost no study, including the RCT
above, has been able to analyse middle ear fluid from
PCV7- compared to PHiD-CV10-vaccinated children, so
more data are needed to support the notion that OM
can be prevented whilst children remain colonised. Data
from animal studies show a site-specific effect of protein
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Table 6 Univariate odds ratios for risk factors for NP carriage of NTHi or Spn in 860 children, adjusted for community
NTHi Spn
Risk Factor (n) OR 95 % CI P OR 95 % CI P
Vaccine group (n = 860)
PCV7 68 % 76 %
PHiD-CV10 73 % 1.3 0.96 to 1.78 0.09 82 % 1.4 1.00 to 2.06 0.05
Age group (n = 860)
< 1 year 71 % 0.98 77 % 0.48
1 to < 2 years 71 % 0.98 0.67 to 1.43 79 % 1.09 0.71 to 1.66
2 to < 3 years 70 % 0.94 0.62 to 1.43 81 % 1.30 0.81 to 2.09
Gender (n = 860)
Male 70 % 78 %
Female 71 % 1.00 0.74 to 1.34 0.98 80 % 1.11 0.79 to 1.57 0.53
Gestational age (n = 760)
> = 32 weeks 71 % 81 %
< 32 weeks 65 % 0.72 0.30 to 1.75 0.47 65 % 0.40 0.16 to 0.98 0.05
Antibiotics prescribed in previous 5 weeks (n = 860)
None 69 % 82 %
Any 74 % 1.30 0.95 to 1.79 0.11 73 % 0.58 0.41 to 0.82 0.002
Crowding (number of additional children less than 5 years of age in household) (n = 670)
0 67 % 0.04 75 % 0.25
1 69 % 1.12 0.76 to 1.66 79 % 1.29 0.83 to 2.00
2 61 % 0.74 0.44 to 1.26 79 % 1.19 0.64 to 2.22
3+ 79 % 1.70 0.97 to 2.36 85 % 1.62 0.83 to 2.23
Child care attendance (n = 673)
< 3 days per week 69 % 78 %
3 or more days per week 72 % 1.18 0.70 to 1.99 0.53 82 % 1.34 0.71 to 2.52 0.37
Sibling history of OM (“runny ears”) (n = 618)
No 68 % 80 %
Yes 70 % 1.11 0.75 to 1.63 0.61 77 % 0.91 0.59 to 1.41 0.68
Child near campfire last week (n = 659)
No 70 % 77 %
Yes 68 % 0.90 0.63 to 1.28 0.56 81 % 1.36 0.89 to 2.09 0.16
Haemoglobin (n = 780)
> =11 mg/dL 68 % 79 %
<11 mg/dL 76 % 1.45 1.02 to 2.07 0.04 80 % 1.04 0.70 to 1.53 0.86
Maternal smoking (n = 673)
No 68 % 79 %
Yes 69 % 1.05 0.75 to 1.48 0.76 78 % 0.97 0.65 to 1.44 0.88
Maternal schooling (n = 528)
Year 10 or less 73 % 78 %
Year 11 or 12 63 % 0.65 0.44 to 0.95 0.03 77 % 0.94 0.61 to 1.47 0.80
Maternal age at birth of this child (n = 649)
> = 21 yrs 69 % 79 %
< 21 yrs 72 % 1.17 0.80 to 1.71 0.42 80 % 1.09 0.70 to 1.69 0.69
Breastfed (n = 678)
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D-dependent adherence [21] which the authors attrib-
uted to the compartment-specific host cell type; epithe-
lial tissue in the nasopharynx being predominantly
ciliated columnar, whereas cells in the middle ear are
primarily non-ciliated and squamous. It was also sug-
gested that load of colonising NTHi may be reduced by
anti-protein D antibodies, limiting disease development
[21]. Failure of PHiD-CV10 to eradicate or protect from
NP carriage of NTHi precludes benefits of herd effects
for the non-vaccinated population. At the same time,
this could be advantageous in terms of maintaining the
integrity of the NP flora, particularly if sterile sites can
be protected.
There remains the possibility that PHiD-CV10 has
more subtly influenced the NP microbiota. Not all NTHi
strains have the hpd gene for protein D expression, the
NTHi immunogenic target of PHiD-CV10 [22]. Thus
vaccine selective pressures may apply with consequent
shifts in the NTHi population. We found that NP car-
riage of Sa was significantly lower in PHiD-CV10-
vaccinated children, which was not replicated in the
middle ear cultures. The NP carriage studies by van den
Bergh et al. and Hammitt et al. found no significant im-
pact of PHiD-CV10 on NP carriage of Sa [19, 20]. Fur-
ther work needs to be done to establish impacts of
vaccination on the human microbiome.
There was no substantial difference in the serotypes
colonising the NP of PCV7 compared to PHiD-CV10-
vaccinated children. There was a high level of serotype
diversity with less than 30 % being PCV13 serotypes. Se-
rotypes 16 F and 19A accounted for 22 % isolates in
each vaccine group. Serotype 16F has been predominant
in NP carriage of adults and children in this population
over decades [23, 24]. In the ED, only serotypes 16F and
23F were common to both vaccine groups. Serotype di-
versity was high and numbers too low to make meaning-
ful comparisons, or to suggest that a clinical difference
may be associated with the shift in serotypes. Interest-
ingly, in a large study in Israel during PCV7 and PCV13
eras, serotype 16F has become the second most common
non-PCV serotype isolated by tympanocentesis from
MEF of children with AOM [25]. Serotype 3 rarely colo-
nises the NP, but is an important cause of AOM. Around
30 % pneumococci recovered from ED of German
PCV7-vaccinated children with spontaneous otorrhoea
were serotype 3 [26]. Serotype 3 was not included in the
PHiD-CV10 formulation following negative efficacy in
the pre-licensure 11Pn-PD vaccine [6]. Although PCV7
does not include serotype 3, reductions in serotype 3
AOM incidence in Israel were seen during the PCV7
era, but interestingly no further reductions were seen in
the PCV13 era [25]. We did not find serotype 3 in the
EDs of PCV7- or PHiD-CV10-vaccinated children in this
study.
Previously our group has enhanced detection of NTHi,
Spn and Mcat in the NP [27] and ED [4] by applying
PCR. Culture results for ED swabs from 55 children with
AOMwiP were 49 % NTHi, 33 % Spn and 4 % Mcat
whereas qPCR identified 89 %, 41 % and 18 % respect-
ively, in ED swabs [4]. For children with OME there is
generally a low rate of culture positivity although NTHi
(8 %) and Mcat (5 %) are dominant [28]. We are not able
to confirm the proportion of OME cases in Aboriginal
children that might be culture positive, but as we de-
tected an increase in OME in PHiD-CV10-vaccinated
children compared to PCV7-vaccinated children, it is
plausible that NTHi persists in the middle ears of these
children, but in a metabolically altered state (for ex-
ample, in biofilm). Data from non-Indigenous Australian
children with recurrent AOM also show a dominance of
NTHi in middle ear effusions by culture (13 %) and PCR
(47 %), compared to Spn (6 % and 6 %, respectively) and
Mcat (6 % and 13 %, respectively) [29]. Similar domin-
ance of NTHi in the MEF of children undergoing tym-
panostomy tube insertion was reported from New
Zealand [30] and in children with recurrent AOM in
Spain [31].
Conclusions
This comparison of NP carriage and ED microbiology in
children vaccinated with PCV7 or PHiD-CV10 (2 or
more doses, or non-mixed schedules) found no
Table 6 Univariate odds ratios for risk factors for NP carriage of NTHi or Spn in 860 children, adjusted for community (Continued)
Never 60 % 65 %
Some 69 % 1.53 0.78 to 2.99 0.21 79 % 2.34 1.14 to 4.80 0.02
Pacifier (n = 671)
Never 70 % 80 %
Some 65 % 0.81 0.53 to 1.25 0.34 70 % 0.52 0.33 to 0.84 0.007
PPV23 (n = 163)a
no 66 % 76 %
yes 74 % 1.5 0.69 to 3.3 0.30 77 % 1.1 0.45 to 2.7 0.83
a163 children > = 18 months of age
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difference in the prevalence of Spn or NTHi NP car-
riage. For children with tympanic membrane perforation
(AOMwiP or CSOM), fewer PHiD-CV10-vaccinated
children had NTHi culture-positive ED than PCV7-
vaccinated children. It is plausible that all PHiD-CV10-
vaccinated children, including those with AOMwoP, had
less NTHi in the middle ear. This would be consistent
with our finding that fewer PHiD-CV10-vaccinated chil-
dren had suppurative OM (AOMwoP, AOMwiP or
CSOM) than PCV7-vaccinated children [1]. Whether
the reduction in NTHi in ear discharge is due to protec-
tion elicited by the NTHi protein D of the PHiD-CV10
vaccine or other factors is not known. This question is
best answered through the conduct of well-designed
RCTs that include microbiological outcome measures.
Synflorix® is a trademark of the GlaxoSmithKline
group of companies.
Prevenar® and Prevenar 13® are trademarks of Pfizer
Inc.
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